Trial Profile
A Double-blind, Randomized, Placebo-controlled Study of the Safety,Tolerability and Pharmacokinetics of Increasing Doses of XC221 After Single and Repeated Oral Administration in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2018
Price :
$35
*
At a glance
- Drugs XC-221 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Pharmenterprises
- 14 Mar 2018 New trial record